rel-(1s,3s,5s)-Cyclohexane-1,3,5-triol

Catalog No. :
ACFXZO365
CAS No. :
50409-12-6
Molecular Formula :
C6H12O3
Molecular Weight :
132.16

IUPAC Name:(1s,3s,5s)-cyclohexane-1,3,5-triol

rel-(1s,3s,5s)-Cyclohexane-1,3,5-triol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$166.00Login to see priceInquiryInquiry
5g97%$436.00Login to see priceInquiryInquiry
10g97%$869.00Login to see priceInquiryInquiry
25g97%$2160.00Login to see priceInquiryInquiry
50g97%$4306.00Login to see priceInquiryInquiry
100g97%$8174.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namerel-(1s,3s,5s)-Cyclohexane-1,3,5-triol
IUPAC Name(1s,3s,5s)-cyclohexane-1,3,5-triol
MDL No.MFCD00043062
Molecular FormulaC6H12O3
Molecular Weight132.16
SMILESO[C@H]1C[C@@H](O)C[C@@H](O)C1
InChI KeyFSDSKERRNURGGO-FPFOFBBKSA-N
SynonymAKOS006276376 | A871571 | CAA04115 | trans-1,3,5-Trihydroxycyclohexane | FS-4315 | CS-0453039 | Q27461691 | SCHEMBL19307787 | SB83876 | Phloroglucitol | A-Trihydroxycyclohexane | A,3 | DTXSID00942577 | SCHEMBL36515 | 1-(4-phenyl-1h-imidazol-2-yl)cyclohexa
CAS No.50409-12-6
PubChem CID230351

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACFXZO365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFXZO365 route product structure diagram
    ACFXZO36550409-12-6
Inquiry

2. ACFXZO365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFXZO365 route product structure diagram
    ACFXZO36550409-12-6
Inquiry

Comments (0)